202 related articles for article (PubMed ID: 26366479)
1. General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials.
Dmitrienko A; Muysers C; Fritsch A; Lipkovich I
J Biopharm Stat; 2016; 26(1):71-98. PubMed ID: 26366479
[TBL] [Abstract][Full Text] [Related]
2. An overview of statistical and regulatory issues in the planning, analysis, and interpretation of subgroup analyses in confirmatory clinical trials.
Hemmings R
J Biopharm Stat; 2014; 24(1):4-18. PubMed ID: 24392975
[TBL] [Abstract][Full Text] [Related]
3. Multiplicity considerations in subgroup analysis.
Dmitrienko A; Millen B; Lipkovich I
Stat Med; 2017 Dec; 36(28):4446-4454. PubMed ID: 28762525
[TBL] [Abstract][Full Text] [Related]
4. Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials.
Lipkovich I; Dmitrienko A; B R
Stat Med; 2017 Jan; 36(1):136-196. PubMed ID: 27488683
[TBL] [Abstract][Full Text] [Related]
5. Subgroups: time to go back to basic statistical principles?
Keene ON; Garrett AD
J Biopharm Stat; 2014; 24(1):58-71. PubMed ID: 24392978
[TBL] [Abstract][Full Text] [Related]
6. Data-Driven Subgroup Identification in Confirmatory Clinical Trials.
Bunouf P; Groc M; Dmitrienko A; Lipkovich I
Ther Innov Regul Sci; 2022 Jan; 56(1):65-75. PubMed ID: 34327673
[TBL] [Abstract][Full Text] [Related]
7. Multiplicity issues in exploratory subgroup analysis.
Lipkovich I; Dmitrienko A; Muysers C; Ratitch B
J Biopharm Stat; 2018; 28(1):63-81. PubMed ID: 29173045
[TBL] [Abstract][Full Text] [Related]
8. A flexible strategy for testing subgroups and overall population.
Alosh M; Huque MF
Stat Med; 2009 Jan; 28(1):3-23. PubMed ID: 18985704
[TBL] [Abstract][Full Text] [Related]
9. Tradeoff-based optimization criteria in clinical trials with multiple objectives and adaptive designs.
Dmitrienko A; Paux G; Pulkstenis E; Zhang J
J Biopharm Stat; 2016; 26(1):120-40. PubMed ID: 26391238
[TBL] [Abstract][Full Text] [Related]
10. Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.
Lin JA; He P
Br Med Bull; 2015 Jun; 114(1):17-27. PubMed ID: 25921239
[TBL] [Abstract][Full Text] [Related]
11. An overview of statistical planning to address subgroups in confirmatory clinical trials.
Koch GG; Schwartz TA
J Biopharm Stat; 2014; 24(1):72-93. PubMed ID: 24392979
[TBL] [Abstract][Full Text] [Related]
12. Subgroup analyses in confirmatory clinical trials: time to be specific about their purposes.
Tanniou J; van der Tweel I; Teerenstra S; Roes KC
BMC Med Res Methodol; 2016 Feb; 16():20. PubMed ID: 26891992
[TBL] [Abstract][Full Text] [Related]
13. Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review.
Ondra T; Dmitrienko A; Friede T; Graf A; Miller F; Stallard N; Posch M
J Biopharm Stat; 2016; 26(1):99-119. PubMed ID: 26378339
[TBL] [Abstract][Full Text] [Related]
14. Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSPI/PSI working group on subgroup analysis.
Dane A; Spencer A; Rosenkranz G; Lipkovich I; Parke T;
Pharm Stat; 2019 Mar; 18(2):126-139. PubMed ID: 30592133
[TBL] [Abstract][Full Text] [Related]
15. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
Mehta C; Schäfer H; Daniel H; Irle S
Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
[TBL] [Abstract][Full Text] [Related]
16. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
17. On sample size determination in multi-armed confirmatory adaptive designs.
Wassmer G
J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570
[TBL] [Abstract][Full Text] [Related]
18. Interpretation of subgroup effects in published trials.
Hancock MJ; Kjaer P; Korsholm L; Kent P
Phys Ther; 2013 Jun; 93(6):852-9. PubMed ID: 23431217
[TBL] [Abstract][Full Text] [Related]
19. Multiplicity considerations for subgroup analysis subject to consistency constraint.
Alosh M; Huque MF
Biom J; 2013 May; 55(3):444-62. PubMed ID: 23585158
[TBL] [Abstract][Full Text] [Related]
20. Bayesian models for subgroup analysis in clinical trials.
Jones HE; Ohlssen DI; Neuenschwander B; Racine A; Branson M
Clin Trials; 2011 Apr; 8(2):129-43. PubMed ID: 21282293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
